{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.3","upperLimit":"28.0","value":"20.1"},{"groupId":"OG001","lowerLimit":"13.8","upperLimit":"22.5","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"85"}],"units":"Participants"}],"description":"DR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date will be used. DR was calculated as \\[the date response ended (i.e. date of PD or death) - first CR or PR date + 1)\\]/30.4. DR would only be calculated for the subgroup of participants with an objective tumor response. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \\<10mm). PR: \\>=30% decrease under baseline of the sum of diameters of all target measurable lesions.The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received letrozole 2.5 milligram (mg) orally QD (once daily) combined with palbociclib 125 mg QD for 21 days of every-28-day cycle, followed by 7 days off treatment.","id":"OG000","title":"Palbociclib Plus Letrozole"},{"description":"Participants received letrozole 2.5 mg orally QD combined with placebo QD for 21 days of every-28-day cycle, followed by 7 days off treatment.","id":"OG001","title":"Placebo Plus Letrozole"}],"paramType":"MEDIAN","populationDescription":"Participants who had tumor response with CR or PR during study.","reportingStatus":"POSTED","timeFrame":"From randomization until end of treatment (up to approximately 2.5 years)","title":"Duration of Response (DR)","type":"SECONDARY","unitOfMeasure":"Months"}